Navigation Links
Combination therapy shows positive response for children with ADHD
Date:1/9/2012

Washington D.C., January 9, 2012 - While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent. A recent study by Dr. Timothy E. Wilens and colleagues, published in the January 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), is the first randomized placebo-controlled trial designed to assess efficacy and safety of guanfacine extended release (GXR) as an adjunct to psychostimulants in children and adolescents diagnosed with ADHD who had a suboptimal response to a psychostimulant alone.

As reported in the article "A Controlled Trial of Extended-release Guanfacine and Psychostimulants for Attention-deficit/hyperactivity disorder," Wilens and colleagues conducted a nine week multicenter, double-blind, placebo-controlled, dose-optimization study, with participants in 59 study sites who continued their stable dose of psychostimulant given in the morning and were randomized to receive GXR in the morning, GXR in the evening, or placebo.

For both morning and evening administration of GXR, subjects receiving GXR plus a psychostimulant showed significantly greater improvement from baseline to endpoint, as measured by the ADHD-Rating Scale IV total score, compared with subjects receiving placebo plus a psychostimulant. In particular, the inattention subscale rating and the hyperactivity/ impulsivity subscales of the ADHD-RS-IV showed significantly greater improvements from baseline in subjects receiving GXR with a psychostimulant compared with subjects receiving placebo plus psychostimulant. Significant benefits of adjunctive administration were observed whether GXR was administered in the morning or evening. No new safety signals emerged after adjunctive administration of GXR with psychostimulants compared with psychostimulants alone.

Reflecting on their resear
'/>"/>

Contact: Mary Billingsley
mbillingsley@jaacap.org
202-966-7300 x105
Elsevier
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Severe alcoholic hepatitis: An effective combination of 2 treatments
2. Combination epigenetic therapy clinical trial results
3. NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth
4. Combination of available tests helps predict Alzheimers disease risk
5. Combination therapies for drug-resistant cancers
6. Combination therapy beneficial for head and neck skin carcinomas, UNC study shows
7. Phase II study shows new cancer drug combination significantly delays breast cancer progression
8. Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
9. Combination therapy rids common infection from implanted medical devices
10. Metformin and exercise combination less effective for glucose control
11. Combination of existing safety checks could greatly reduce radiotherapy errors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... unveiled a new partnership with Axway to ... migration professionals and technologists to address the ... a timely and cost-effective manner.BELLEVUE, Wash., May ... healthcare electronic transactions simplification and systems interoperability, ...
... May 20 Industry-leading and renowned laparoscopic bariatric ... was recently selected by medical device manufacturers to ... the Tarrant County Region.Dr. Smith continues to lead ... procedures, known as SILS (Single Incision Laparoscopic Surgery), ...
... 20 Recondo Technology, a leading provider of ... announced that Harry Gambill and Jeff Fritz have ... http://www.newscom.com/cgi-bin/prnh/20090325/LA89162LOGO )Harry Gambill began with TransUnion in 1985 ... to 2007. During his 16-year tenure, TransUnion grew ...
... Lloyd H. Malchow Join Digirad Board of DirectorsPOWAY, Calif., ... ) today announced that it has named veteran healthcare ... its Board of Directors, effective immediately. The addition of ... total of seven members."Steve and Lloyd both have the ...
... how ARX,s CoSign® digital signatures fully integrate with Adobe LiveCycle® ES, ... processes. , ... San Francisco, CA (PRWEB) May 20, ... provider of the CoSign digital signature (standard electronic signature) solution ...
... Healthcommunities.com, Inc., announces the recent addition of a New ... neurologychannel.com. This newly updated section features important information about pain ... who suffer with tension headache, cluster headache, migraine, and other ... ...
Cached Medicine News:Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4Health News:Dr. Adam Smith Chosen to Help Introduce No-Scar Surgical Weight-Loss Innovations 2Health News:Recondo Technology Announces Two New Board Members 2Health News:Digirad Names Two Veteran Healthcare Executives to Board 2Health News:Digirad Names Two Veteran Healthcare Executives to Board 3Health News:Digirad Names Two Veteran Healthcare Executives to Board 4Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 2Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 3Health News:Headache Sufferers Turn to Neurologychannel for Reliable Information about New Headache Treatments 2Health News:Headache Sufferers Turn to Neurologychannel for Reliable Information about New Headache Treatments 3
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Today FRC Action joined 19 pro-life groups in a letter sent to Food ... consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency ... Tom McClusky ... the following comments: , , , ...
... INDIANAPOLIS , July 28 Eli Lilly and Company (NYSE: ... the Federal Circuit has upheld a prior ruling by the U.S. District Court ... invalid. , , , ... ruling by the U.S. Court of Appeals regarding Gemzar,s method-of-use patent. We continue ...
Cached Medicine Technology:FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: